You are going to the DESC meeting !
{{data.first_name}}, we are looking forward to seeing you in Berkeley.
Please check your emails for confirmation of your payment.
You can find travel and hotel information on the meeting
Confluence page
.
the LOC


{% extends "html/_layouts/index.html" %} {% block jumbotron %}
There is a pro version available which adds new components, a number of page layouts and more color palettes: Check out Charming Pro


Founded in 2004 in Ferrara, Italy, MEEO started its activity providing products and services for atmospheric pollution monitoring, extending successively its application domain to the Earth surface mapping. Since 2006 MEEO is a consolidated partner of the European Space Agency and provides its services to public and private entities.
General information on the production of air quality forecast and analysis over Europe. The MACC regional air quality (http://macc-raq.gmes-atmosphere.eu) production is based on seven state-of-the-art numerical air quality models developed in Europe: CHIMERE by INERIS (France), EMEP by MET Norway (Norway), EURAD-IM by University of Cologne (Germany), LOTOS-EUROS by KNMI (Netherlands), MATCH by SMHI (Sweden), MOCAGE by Météo-France (France) and SILAM at FMI(Finland). The seven model forecasts and analyses are combined via an ensemble approach, that provides on average better estimates of air pollutant concentrations than the individual models.
The Climate Data Service provides MACC regional air quality forecasts over Europe (30°N - 70°N, 25°W - 45°E): ozone (O3), nitrogen dioxide (NO2), sulphur dioxide (SO2), carbon monoxide (CO), particulate matters (PM10 and PM2.5) at surface, at 500m, 1000m and 3000m altitude, on an hourly basis.


|
IVT
|
Data structure for the representation of SIFT features. More...
#include <SIFTFeatureEntry.h>
Public Member Functions | |
| CSIFTFeatureEntry (float *data, float x, float y, float angle, float scale) | |
| CSIFTFeatureEntry (float x, float y, float angle, float scale) | |
| CSIFTFeatureEntry () | |
| CSIFTFeatureEntry (const CSIFTFeatureEntry &featureEntry) | |
| eFeatureType | GetType () const |
| CFeatureEntry * | Clone () const |
| float | Error (const CDynamicArrayElement *pElement) const |
| Public Member Functions inherited from CFeatureEntry | |
| CFeatureEntry (int nSize, float x, float y, float angle, float scale, Vec3d point3d=Math3d::zero_vec) | |
| CFeatureEntry (const float *pFeature, int nSize, float x, float y, float angle, float scale, Vec3d point3d=Math3d::zero_vec) | |
| CFeatureEntry (const CFeatureEntry &featureEntry) | |
| ~CFeatureEntry () | |
| virtual bool | ReadFromFileOld (FILE *pFile) |
| virtual bool | ReadFromFile (FILE *pFile) |
| virtual bool | WriteToFile (FILE *pFile) const |
| int | GetSize () const |
| virtual int | GetSizeOnDisk () const |
| Public Member Functions inherited from CDynamicArrayElement | |
| CDynamicArrayElement () | |
| virtual | ~CDynamicArrayElement () |
| virtual bool | Equivalent (const CDynamicArrayElement *pElement) const |
Additional Inherited Members | |
| Public Types inherited from CFeatureEntry | |
| enum | eFeatureType { tSIFT, tMSER, tPatch, tCCH, tLCCH, tNLCCH } |
| Public Attributes inherited from CFeatureEntry | |
| float * | m_pFeature |
| Vec2d | point |
| Vec3d | point3d |
| float | angle |
| float | scale |
| Public Attributes inherited from CDynamicArrayElement | |
| bool | bDelete |
| Protected Attributes inherited from CFeatureEntry | |
| int | m_nSize |
Data structure for the representation of SIFT features.
Definition at line 62 of file SIFTFeatureEntry.h.
|
inline |
Definition at line 66 of file SIFTFeatureEntry.h.
|
inline |
Definition at line 70 of file SIFTFeatureEntry.h.
|
inline |
Definition at line 74 of file SIFTFeatureEntry.h.
|
inline |
Definition at line 78 of file SIFTFeatureEntry.h.
|
inlinevirtual |
Implements CFeatureEntry.
Definition at line 89 of file SIFTFeatureEntry.h.
|
inlinevirtual |
Implements CFeatureEntry.
Definition at line 94 of file SIFTFeatureEntry.h.
|
inlinevirtual |
Implements CFeatureEntry.
Definition at line 84 of file SIFTFeatureEntry.h.


--- layout: default title: home description: Veterinarian, research, data, epi, design, also other things; this is my website image: http://tteoh.com/public/quaver-avatar.png --- {% for post in paginator.posts %}


Toggle navigation
HLXRT
Module stacks
Pure Mathematics
Introduction to analysis
Differential equations
Linear algebra
Multvariable calculus
Abstract algebra
Elementary topology
Real analysis
Applied Mathematics
Calculus
Differential equations
Linear algebra
Multvariable calculus
Abstract algebra
Mathematical statistics
Numerical analysis
Bioinformatics
Calculus
CS probability
Structure and reactivity
Genetics
Foundations of computing
Mechanics
Programming methodology
Computer Engineering
Calculus
Foundations of computing
CS probability
Mechanics
Electricity and magnetism
Programming languages
Operating systems
Computational Theory
Calculus
Foundations of computing
Operating systems
Mechanics
Electricity and magnetism
PL Theory and applications
Algorithms and data structures.
Master of Science in Mathematics
Calculus
Foundations of computing
Operatings Systems
Mechanics
Electricity and magnetism
PL Theory and applications
Algorithms and data structures.
Master of Science in Computer Science
Calculus
Foundations of computing
Operating systems
Mechanics
Electricity and magnetism
PL theory and applications
Algorithms and data structures.
Master of Science in Computer Science
Calculus
Foundations of computing
Operating systems
Mechanics
Electricity and magnetism
PL theory and applications
Algorithms and data structures.
apps
hILIXRT
@hilixrt
SIGNOUT
Hilix Admin
My Portfolio
Hilix Database
Account settings
Manage storage space
Nebula 1.0
database
Toggle navigation
Mathematics
Applied mathematics
Statistics
Algebra
Analysis
Category theory
Combinatorics
Control theory
Cry...
Cryptography
Dynamical systems
Game theory
Geometry
Data scien...
Data science
Mathematical biology
Mathematical chemistry
Mathemati...
Physics
Computer science
Linguistic theory
Algebra
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Analysis
—
Calculus
—
Real Analysis
—
Measure Theory
—
Complex Analysis
—
Harmonic Analysis
—
Numerical Analysis
—
Functional Analysis
—
Calculus of Variations
—
Differential Equations
—
Multivariable Calculus
Category theory
—
Objects
—
Functors
—
Categories
—
Morphisms
—
Limits and colimits
—
Equivalent categories
—
Universal constructions
—
Natural transformations
—
Applications of categories
—
Higher–dimensional categories
Combinatorics
—
Order theory
—
Graph theory
—
Design theory
—
Matroid theory
—
Partition theory
—
Finite geometry
—
Analytic combinatorics
—
Infinitary combinatorics
—
Algebraic combinatorics
—
Enumerative combinatorics
Control theory
—
Stability
—
OL/CL control
—
Control strategies
—
System interfacing
—
Analysis techniques
—
Control specification
—
Linear control theory
—
Classical control theory
—
Nonlinear control theory
—
Controlability / observability
Cryptography
—
Cryptanalysis
—
Cryptosystems
—
Steganography
—
Integer factorization
—
Cryptographic primitives
—
Public–key cryptography
—
Quantom Cryptography
—
Multivariate cryptography
—
Symmetric–key cryptography
Dynamical Systems
—
Local dynamics
—
Ergodic systems
—
Bifurcation theory
—
Complex dynamics
—
Behavioral Modeling
—
Linear dynamical systems
—
Discrete dnamical systems
—
Abstract dynamical systems
—
Multidimensional generalization
Game theory
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Geometry
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Graph theory
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Mathematical biology
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Mathematical chemistry
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Mathematical economics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Mathematical finance
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Mathematical optimization
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Mathematical physics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Mathematical statistics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Number theory
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Probability theory
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Topology
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Physics
Astrophysics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Atomic physics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Classical mechanics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Condensed matter physics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Geophysics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
High energy physics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Molecular physics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Optical physics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Particle physics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Quantum theory
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Relativity theory
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Statistical machanics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Computer science
Artificial Intelligence
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Biocomputation
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Computational chemistry
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Computational economics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Computational physics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Information technology
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Programming language theory
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Sensory computation
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Software engineering
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Symbolic computation systems
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Systems architecture
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Theoretical computer science
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Linguistics
Computational linguistics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Corpus linguistics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Mathematical linguistics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Morphology
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Phonology
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Semantics
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Syntax
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory
Typology
—
Foundations
—
Linear Algebra
—
Abstract Algebra
—
Universal Algebra
—
Computer Algebra
—
Algebraic Topology
—
Differential Algebra
—
Algebraic Geometry
—
Combinatorial Algebra
—
Algebraic Number Theory


|
| | CSpinner (CGame game, String text, ArrayList< String > options) |
| | Spinner constructor. More...
|
| |
| | CSpinner (CGame game, String text, ArrayList< String > options, Vector2 margin) |
| |
| final void | LayoutElements () |
| | Lays out the elements of the spinner horizontally. More...
|
| |
| void | Update (CGame game, Vector2 translation) |
| | Updates the spinner and changes the selected option if necessary. More...
|
| |
| final void | ChangeSelectedOption (EPlusOrMinus choice) |
| | Changes the selected option to next or previous option. More...
|
| |
| final String | SelectedOption () |
| | Gets the selected option. More...
|
| |
| final int | LongestHorizontalSize () |
| | Gets the longest horizontal sized option. More...
|
| |
| final void | LongestHorizontalSize (int size) |
| | Sets the longest horizontal sized option. More...
|
| |
| final CUIElement | OptionName () |
| | Gets the option name button. More...
|
| |
|
| CUIElement () |
| | CUIElement constructor to initialize element pointers.
|
| |
|
void | Update (CGame game) |
| |
|
void | Update (CGame game, Vector2 translation) |
| |
| void | Draw (CGame game) |
| | Draws the element given its computed translation. More...
|
| |
|
void | Draw (CGame game, Vector2 translation) |
| |
|
void | CUIElementDraw (CGame game, Vector2 translation) |
| |
| final void | Anchor (Vector2 anchor) |
| | Sets the anchor (0, 0) -> Top Left, (1, 1) -> Bottom Right. More...
|
| |
|
final void | UpdateTranslation () |
| | Recomputes the translation given the size, position, and anchor.
|
| |
| final void | Position (Vector2 position) |
| | Sets the position. More...
|
| |
| final void | Size (Vector2 size) |
| | Sets the size. More...
|
| |
| final Vector2 | Anchor () |
| | The Anchor. More...
|
| |
| final Vector2 | Position () |
| | The Position. More...
|
| |
| final Vector2 | Size () |
| | The Size. More...
|
| |
| final Vector2 | Translation () |
| | The computed translation. More...
|
| |
| final boolean | IsHovered () |
| | If the mouse is over this element. More...
|
| |
| final boolean | IsPressed () |
| | If the mouse or enter key pressed this element. More...
|
| |
| void | AddChildElement (CUIElement child) |
| | Adds a child element to this element. More...
|
| |
| void | RemoveChildElement (CUIElement child) |
| | Removes a child from this element. More...
|
| |
|
void | ClearChildren () |
| | Removes all children from this element.
|
| |
| final java.util.LinkedList< CUIElement > | Children () |
| | Gets the children of this element. More...
|
| |
| final CUIElement | DownElement () |
| | Gets down pointer. More...
|
| |
| final CUIElement | UpElement () |
| | Gets up pointer. More...
|
| |
| final void | LeftElement (CUIElement element) |
| | Sets left pointer to the element left. More...
|
| |
| final CUIElement | LeftElement () |
| | Gets left pointer. More...
|
| |
| final void | RightElement (CUIElement element) |
| | Sets right pointer to the element right. More...
|
| |
| final CUIElement | RightElement () |
| | Gets right pointer. More...
|
| |
| final boolean | IsSelected () |
| | If the element has been selected. More...
|
| |
|
final void | ConnectVertically (CUIElement other) |
| | Sets this's up pointer to other, other's down pointer to this.
|
| |
| final void | UpElement (CUIElement element) |
| | Sets up pointer to the element above. More...
|
| |
| final void | DownElement (CUIElement element) |
| | Sets down pointer to the element below. More...
|
| |
| CUIElement | DetermineSelected (Vector2 mousePosition) |
| | Determines which UI element is selected given the computed translation. More...
|
| |
|
CUIElement | DetermineSelected (Vector2 mousePosition, Vector2 translation) |
| |
Spinner UI Element class.


PVCollection News Feed Test
Mocked up news feed to test the PVCollection and displaying changed items.
Title
Deck
Body
Some check item
Submit
Set batch 2
List Debug


BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE - butalbital, aspirin, caffeine and codeine phosphate capsule
bryant ranch prepack
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is supplied in capsule form for oral administration.
Each capsule contains the following active ingredients:
Butalbital, USP
.....................................................................................
50 mg
Aspirin, USP
.......................................................................................
325 mg
Caffeine, USP
.......................................................................................
40 mg
Codeine Phosphate, USP
...................................................................... 30 mg
Inactive Ingredients: Corn Starch, D and C Red No. 28, D and C Yellow No. 10, FD and C Blue No. 1, FD and C Red No. 40, Gelatin, Microcrystalline Cellulose, Sodium Lauryl Sulfate, Stearic Acid, Talc, and Titanium Dioxide.
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is a combination drug product intended as a treatment for tension headache. ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) consists of a fixed combination of caffeine 40mg, butalbital 50mg, aspirin 325mg, and codeine phosphate 30mg. The role each component plays in the relief of the complex of symptoms known as tension headache is not completely understood.
PharmacokineticsBioavailabilityThe bioavailability of the components of the fixed combination of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is identical to their bioavailability when Butalbital, Aspirin, and Caffeine Capsules, USP and codeine are administered separately in equivalent molar doses.
The behavior of the individual components is described below.
AspirinThe systemic availability of aspirin after an oral dose is highly dependent on the dosage form, the presence of food, the gastric emptying time, gastric pH, antacids, buffering agents, and particle size. These factors affect not necessarily the extent of absorption of total salicylates but more the stability of aspirin prior to absorption.
During the absorption process and after absorption, aspirin is mainly hydrolyzed to salicylic acid and distributed to all body tissues and fluids, including fetal tissues, breast milk and the central nervous system (CNS). Highest concentrations are found in plasma, liver, renal cortex, heart, and lung. In plasma, about 50%-80% of the salicylic acid and its metabolites are loosely bound to plasma proteins.
The clearance of total salicylates is subject to saturable kinetics; however, first-order elimination kinetics are still a good approximation for doses up to 650 mg. The plasma half-life for aspirin is about 12 minutes and for salicylic acid and/or total salicylates is about 3 hours.
The elimination of therapeutic doses is through the kidneys either as salicylic acid or other biotransformation products. The renal clearance is greatly augmented by an alkaline urine as is produced by concurrent administration of sodium bicarbonate or potassium citrate.
The biotransformation of aspirin occurs primarily in the hepatocytes. The major metabolites are salicyluric acid (75%), the phenolic and acyl glucuronides of salicylate (15%), and gentisic and gentisuric acid (1%). The bioavailability of the aspirin component of butalbital, aspirin, caffeine and codeine phosphate capsules is equivalent to that of a solution except for a slower rate of absorption. A peak concentration of 8.80 mcg/mL was obtained at 40 minutes after a 650 mg dose.
See OVERDOSAGE for toxicity information.
CodeineCodeine is readily absorbed from the gastrointestinal tract. It is rapidly distributed from the intravascular spaces to the various body tissues, with preferential uptake by parenchymatous organs such as the liver, spleen and kidney. Codeine crosses the blood-brain barrier, and is found in fetal tissue and breast milk. The plasma concentration does not correlate with brain concentration or relief of pain, however, codeine is not bound to plasma proteins and does not accumulate in body tissues.
The plasma half-life is about 2.9 hours. The elimination of codeine is primarily via the kidneys, and about 90% of an oral dose is excreted by the kidneys within 24 hours of dosing. The urinary secretion products consist of free and glucuronide-conjugated codeine (about 70%), free and conjugated norcodeine (about 10%), free and conjugated morphine (about 10%), normorphine (4%), and hydrocodone (1%). The remainder of the dose is excreted in the feces.
At therapeutic doses, the analgesic effect reaches a peak within 2 hours and persists between 4 and 6 hours.
The bioavailability of the codeine component of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is equivalent to that of a solution. Peak concentrations of 198 ng/mL were obtained at 1 hour after a 60 mg dose.
SeE OVERDOSAGE for toxicity information.
ButalbitalButalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most of the tissues in the body. Barbiturates, in general, may appear in breast milk and readily cross the placental barrier. They are bound to plasma and tissue proteins to a varying degree and binding increases directly as a function of lipid solubility.
Elimination of butalbital is primarily via the kidney (59%-88% of the dose) as unchanged drug or metabolites. The plasma half-life is about 35 hours. Urinary excretion products included parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8% of the dose), products with the barbituric acid ring hydrolyzed with excretion of urea (about 14% of the dose), as well as unidentified materials. Of the material excreted in the urine, 32% was conjugated.
The bioavailability of the butalbital component of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is equivalent to that of a solution except for a decrease in the rate of absorption. A peak concentration of 2,020 ng/mL is obtained at about 1.5 hours after a 100 mg dose.
The in vitro plasma protein binding of butalbital is 45% over the concentration range of 0.5 - 20 mcg/mL. This falls within the range of plasma protein binding (20% to 45%) reported with other barbiturates such as phenobarbital, pentobarbital, and secobarbital sodium. The plasma-to-blood concentration ratio was almost unity indicating that there is no preferential distribution of butalbital into either plasma or blood cells.
See OVERDOSAGE for toxicity information.
CaffeineLike most xanthines, caffeine is rapidly absorbed and distributed in all body tissues and fluids, including the CNS, fetal tissues, and breast milk.
Caffeine is cleared rapidly through metabolism and excretion in the urine. The plasma half-life is about 3 hours. Hepatic biotransformation prior to excretion results in about equal amounts of 1-methylxanthine and 1-methyluric acid. Of the 70% of the dose that has been recovered in the urine, only 3% was unchanged drug.
The bioavailability of the caffeine component for ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is equivalent to that of a solution except for a slightly longer time to peak. A peak concentration of 1,660 ng/mL was obtained in less than an hour for an 80 mg dose.
See OVERDOSAGE for toxicity information.
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is indicated for the relief of the symptom complex of tension (or muscle contraction) headache.
Evidence supporting the efficacy of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is derived from 2 multi-clinic trials that compared patients with tension headache randomly assigned to 4 parallel treatments: ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), codeine, (Butalbital, Aspirin, and Caffeine Capsules, USP), and placebo. Response was assessed over the course of the first 4 hours of each of 2 distinct headaches, separated by at least 24 hours. ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) proved statistically significantly superior to each of its components ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) and to placebo on measures of pain relief.
Evidence supporting the efficacy and safety of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable.
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is contraindicated under the following conditions:
Therapeutic doses of aspirin can cause anaphylactic shock and other severe allergic reactions. It should be ascertained if the patient is allergic to aspirin, although a specific history of allergy may be lacking.
Significant bleeding can result from aspirin therapy in patients with peptic ulcer or other gastrointestinal lesions, and in patients with bleeding disorders.
Aspirin administered pre-operatively may prolong the bleeding time.
In the presence of head injury or other intracranial lesions, the respiratory depressant effects of codeine and other narcotics may be markedly enhanced, as well as their capacity for elevating cerebrospinal fluid pressure. Narcotics also produce other CNS depressant effects, such as drowsiness, that may further obscure the clinical course of patients with head injuries.
Codeine or other narcotics may obscure signs on which to judge the diagnosis or clinical course of patients with acute abdominal conditions.
Butalbital and codeine are both habit-forming and potentially abusable. Consequently, the extended use of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is not recommended.
Results from epidemiologic studies indicate an association between aspirin and Reye's Syndrome. Caution should be used in administering this product to children, including teenagers, with chicken pox or flu.
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) should be prescribed with caution for certain special-risk patients such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, coagulation disorders, or head injuries, elevated intracranial pressure, acute abdominal conditions, hypothyroidism, urethral stricture, Addison's disease, prostatic hypertrophy, and peptic ulcer.
Aspirin should be used with caution in patients on anticoagulant therapy and in patients with underlying hemostatic defects.
Precautions should be taken when administering salicylates to persons with known allergies. Hypersensitivity to aspirin is particularly likely in patients with nasal polyps, and relatively common in those with asthma.
Ultra-rapid Metabolizers of CodeineSome individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion or shallow breathing.
The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1-10% in Caucasians, 3% in African Americans, and 16-28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.
When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and should inform their patients about these risks and the signs of morphine overdose. (See PRECAUCTIONS, Nursing Mothers).
Information for PatientsPatients should be informed that this combination product contains aspirin and should not be taken by patients with an aspirin allergy.
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) may impair the mental and/or physical abilities required for performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP).
Alcohol and other CNS depressants may produce an additive CNS depression when taken with ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), and should be avoided.
Codeine and butalbital may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.
For information on use in geriatric patients, refer to PRECAUTIONS,Geriatric use.
Caution patients that some people have a variation in a liver enzyme and change codeine into morphine more rapidly and completely than other people. These people are ultra-rapid metabolizers and are more likely to have higher-than-normal levels of morphine in their blood after taking codeine which can result in overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. In most cases, it is unknown if someone is an ultra-rapid codeine metabolizer.
Nursing mothers taking codeine can also have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Instruct nursing mothers to watch for signs of morphine toxicity in their infants including increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the baby's doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).
Laboratory TestsIn patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.
Drug InteractionsThe CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance.
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) may enhance the effects of:
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) may diminish the effects of:
Uricosuric agents such as probenecid and sulfinpyrazone, reducing their effectiveness in the treatment of gout. Aspirin competes with these agents for protein binding sites.
Drug/Laboratory Test InteractionsAspirinAspirin may interfere with the following laboratory determinations in blood: serum amylase, fasting blood glucose, cholesterol, protein, serum glutamic-oxalacetic transaminase (SGOT), uric acid, prothrombin time and bleeding time. Aspirin may interfere with the following laboratory determinations in urine: glucose, 5-hydroxy-indoleacetic acid, Gerhardt ketone, vanillylmandelic acid (VMA), uric acid, diacetic acid, and spectrophotometric detection of barbiturates.
CodeineCodeine may increase serum amylase levels.
Carcinogenesis, Mutagenesis, Impairment of FertilityAdequate long-term studies have been conducted in mice and rats with aspirin, alone or in combination with other drugs, in which no evidence of carcinogenesis was seen. No adequate studies have been conducted in animals to determine whether aspirin has a potential for mutagenesis or impairment of fertility. No adequate studies have been conducted in animals to determine whether butalbital has a potential for carcinogenesis, mutagenesis, or impairment of fertility.
Usage in PregnancyTeratogenic EffectsPregnancy Category CAnimal reproduction studies have not been conducted with butalbital, aspirin, caffeine and codeine phosphate. It is also not known whether this combination product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only when clearly needed.
Nonteratogenic EffectsAlthough ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) was not implicated in the birth defect, a female infant was born with lissencephaly, pachygyria and heterotopic gray matter. The infant was born 8 weeks prematurely to a woman who had taken an average of 90 ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) each month from the first few days of pregnancy. The child's development was mildly delayed and from one year of age she had partial simple motor seizures.
Withdrawal seizures were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last 2 months of pregnancy. Butalbital was found in the infant's serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further seizure or other withdrawal symptoms.
Studies of aspirin use in pregnant women have not shown that aspirin increases the risk of abnormalities when administered during the first trimester of pregnancy. In controlled studies involving 41,337 pregnant women and their offspring, there was no evidence that aspirin taken during pregnancy caused stillbirth, neonatal death or reduced birth weight. In controlled studies of 50,282 pregnant women and their offspring, aspirin administration in moderate and heavy doses during the first four lunar months of pregnancy showed no teratogenic effect.
Reproduction studies have been performed in rabbits and rats at doses up to 150 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to codeine.
Therapeutic doses of aspirin in pregnant women close to term may cause bleeding in mother, fetus, or neonate. During the last 6 months of pregnancy, regular use of aspirin in high doses may prolong pregnancy and delivery.
Labor and DeliveryIngestion of aspirin prior to delivery may prolong delivery or lead to bleeding in the mother or neonate. Use of codeine during labor may lead to respiratory depression in the neonate.
Nursing MothersAspirin, caffeine, barbiturates and codeine are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of potential for serious adverse reactions in nursing infants from ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. Despite the common use of codeine products to manage postpartum pain, reports of adverse events in infants are rare. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine's active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants.
The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1-10% in Caucasians, 3% in African Americans, and 16-28% in North Africans, Ethiopians and Arabs. Data is not available for other ethnic groups.
The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding.
Pediatric UseSafety and effectiveness in pediatric patients have not been established.
Geriatric UseClinical studies of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Butalbital is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
The most commonly reported adverse events associated with the use of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) and not reported at an equivalent incidence by placebo-treated patients were nausea and/or abdominal pain, drowsiness and dizziness.
Associated with Treatment DiscontinuationOf the 382 patients treated with ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) in controlled clinical trials, three (0.8%) discontinued treatment with ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) because of adverse events. One patient each discontinued treatment for the following reasons: gastrointestinal upset; lightheadedness and heavy eyelids; and drowsiness and generalized tingling.
Incidence in Controlled Clinical TrialsThe following table summarizes the incidence rates of the adverse events reported by at least 1% of the ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) treated patients in controlled clinical trials comparing ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) to placebo, and provides a comparison to the incidence rates reported by the placebo-treated patients.
The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators.
| Incidence Rate of Adverse Events | ||
|---|---|---|
| Body System/Adverse Event | Butalbital, Aspirin, Caffeine, and Codeine Phosphate,
USP (N=382) |
Placebo (N=377) |
| Central Nervous | ||
| Drowsiness | 2.4% | 0.5% |
| Dizziness/Lightheadedness | 2.6% | 0.5% |
| Intoxicated Feeling | 1.0% | 0% |
| Gastrointestinal | ||
| Nausea/Abdominal Pain | 3.7% | 0.8% |
The listing that follows represents the proportion of the 382 patients exposed to ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) while participating in the controlled clinical trials who reported, on at least one occasion, an adverse event of the type cited. All reported adverse events, except those already presented in the previous table, are included. It is important to emphasize that, although the adverse events reported did occur while the patient was receiving ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), the adverse events were not necessarily caused by ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP).
Adverse events are classified by body system and frequency, "Frequent" is defined as an adverse event which occurred in at least 1/100 (1%) of the patients; all adverse events listed in the previous table are frequent.
"Infrequent" is defined as an adverse event that occurred in less than 1/100 patients but at least 1/1000 patients. All adverse events tabulated below are classified as infrequent.
Central Nervous System: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness and sluggishness.
Autonomic Nervous System: dry mouth and hyperhidrosis.
Gastrointestinal: vomiting, difficulty swallowing, and heartburn.
Cardiovascular: tachycardia.
Musculoskeletal: leg pain and muscle fatigue.
Genitourinary: diuresis.
Miscellaneous: pruritus, fever, earache, nasal congestion, and tinnitus.
Voluntary reports of adverse drug events, temporally associated with ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), that have been received since market introduction and that were not reported in clinical trials by the patients treated with ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP), are listed below. Many or most of these events may have no causal relationship with the drug and are listed according to body system.
Central Nervous System: abuse, addiction, anxiety, depression, disorientation, hallucination, hyperactivity, insomnia, libido decrease, nervousness, neuropathy, psychosis, sedation, sexual activity increase, slurred speech, twitching, unconsciousness, vertigo.
Autonomic Nervous System: epistaxis, flushing, miosis, salivation.
Gastrointestinal: anorexia, appetite increased, constipation, diarrhea, esophagitis, gastroenteritis, gastrointestinal spasm, hiccup, mouth burning, pyloric ulcer.
Cardiovascular: chest pain, hypotensive reaction, palpitations, syncope.
Skin: erythema, erythema multiforme, exfoliative dermatitis, hives, rash, toxic epidermal necrolysis.
Urinary: kidney impairment, urinary difficulty.
Miscellaneous: allergic reaction, anaphylactic shock, cholangiocarcinoma, drug interaction with erythromycin (stomach upset), edema.
The following adverse drug events may be borne in mind as potential effects of the components of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP). Potential effects of high dosage are listed in the OVERDOSAGE section of this insert.
Aspirin: occult blood loss, hemolytic anemia, iron deficiency anemia, gastric distress, heartburn, nausea, peptic ulcer, prolonged bleeding time, acute airway obstruction, renal toxicity when taken in high doses for prolonged periods, impaired urate excretion, hepatitis.
Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia.
Codeine: nausea, vomiting, drowsiness, lightheadedness, constipation, pruritus.
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) is controlled by the Drug Enforcement Administration and is classified under Schedule III.
Abuse and DependenceCodeineCodeine can produce drug dependence of the morphine type and, therefore, has the potential for being abused. Psychological dependence, physical dependence, and tolerance may develop upon repeated administration and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic medications.
ButalbitalBarbiturates may be habit-formingTolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1,500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than twofold. As this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.
The toxic effects of acute overdosage of ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) are attributable mainly to the barbiturate and codeine components, and, to a lesser extent, aspirin. Because toxic effects of caffeine occur in very high dosages only, the possibility of significant caffeine toxicity from ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) overdosage is unlikely.
Signs and SymptomsSymptoms attributable to acute barbiturate poisoning include drowsiness, confusion, and coma; respiratory depression; hypotension; hypovolemic shock. Symptoms attributable to acute aspirin poisoning include hyperpnea; acid-base disturbances with development of metabolic acidosis; vomiting and abdominal pain; tinnitus, hyperthermia; hypoprothrombinemia; restlessness; delirium; convulsions. Acute caffeine poisoning may cause insomnia, restlessness, tremor, and delirium; tachycardia and extrasystoles. Symptoms of acute codeine poisoning include the opioid triad of: pinpoint pupils, marked depression of respiration, and loss of consciousness. Convulsions may occur.
TreatmentThe following paragraphs describe one approach to the treatment of overdosage with ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP). However, because strategies for the management of an overdose continually evolve, consultation with a regional poison control center is strongly encouraged.
Treatment consists primarily of management of barbiturate intoxication, reversal of the effects of codeine, and the correction of the acid-base imbalance due to salicylism. Vomiting should be induced mechanically or with emetics in the conscious patient. Gastric lavage may be used if the pharyngeal and laryngeal reflexes are present and if less than 4 hours have elapsed since ingestion. A cuffed endotracheal tube should be inserted before gastric lavage of the unconscious patient and when necessary to provide assisted respiration. Diuresis, alkalinization of the urine, and correction of electrolyte disturbances should be accomplished through administration of intravenous fluids such as 1% sodium bicarbonate and 5% dextrose in water.
Meticulous attention should be given to maintaining adequate pulmonary ventilation. The value of vasopressor agents such as Norepinephrine or Phenylephrine Hydrochloride in treating hypotension is questionable since they increase vasoconstriction and decrease blood flow. However, if prolonged support of blood pressure is required, Norepinephrine Bitartrate (Levophed®) may be given I.V. with the usual precautions and serial blood pressure monitoring. In severe cases of intoxication, peritoneal dialysis, hemodialysis, or exchange transfusion may be lifesaving. Hypoprothrombinemia should be treated with vitamin K, intravenously.
Methemoglobinemia over 30% should be treated with methylene blue by slow intravenous administration.
Naloxone, a narcotic antagonist, can reverse respiratory depression and coma associated with opioid overdose. Typically, a dose of 0.4 to 2 mg is given parenterally and may be repeated if an adequate response is not achieved. Since the duration of action of codeine may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.
Up-to-date information about the treatment of overdose can be obtained from a Certified Regional Poison Control Center. Telephone numbers of Certified Regional Poison Control Centers are listed in the Physicians' Desk Reference®.
Toxic and Lethal Doses (for adults)Butalbital: toxic dose 1 g (20 capsules); lethal dose 2-5 g
Aspirin: toxic blood level greater than 30 mg/100 mL; lethal dose 10-30 g
Caffeine: toxic dose greater than 1 g; (25 capsules); lethal dose unknown
Codeine: toxic dose 240 mg (8 capsules); lethal dose 0.5-1 g
One or 2 capsules every 4 hours. Total daily dosage should not exceed 6 capsules. Extended and repeated use of this product is not recommended because of the potential for physical dependence.
ASCOMP® with Codeine (Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP) are available as listed below:
NDC NBR CAPSULES PER BOTTLE
63629-2952-1 30
63629-2952-2 20
63629-2952-3 90
63629-2952-4 60
Store and DispenseBelow 25°C (77°F); tight container. Protect from moisture.
A Schedule III Controlled Drug Substance.|
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE
butalbital, aspirin, caffeine and codeine phosphate capsule | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
|
| Labeler - bryant ranch prepack (171714327) |
| Registrant - bryant ranch prepack (171714327) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| bryant ranch prepack | 171714327 | repack(63629-2952) |


|
|
Game Info:
GameId: {{gameId}}
Round: {{round}}
Black Ninja Racer Score: {{blackScore}}
Red Ninja Racer Score: {{redScore}}
White Ninja Racer Score: {{whiteScore}}
Blue Ninja Racer Score: {{blueScore}}
It: {{it}}
|
|
| {{OneOne|safe}} |
{{OneTwo|safe}} |
{{OneThree|safe}} |
{{OneFour|safe}} |
{{OneFive|safe}} |
{{OneSix|safe}} |
{{TwoOne|safe}} |
{{TwoTwo|safe}} |
{{TwoThree|safe}} |
{{TwoFour|safe}} |
{{TwoFive|safe}} |
{{TwoSix|safe}} |
| {{ThreeOne|safe}} |
{{ThreeTwo|safe}} |
{{ThreeThree|safe}} |
{{ThreeFour|safe}} |
{{ThreeFive|safe}} |
{{ThreeSix|safe}} |
{{FourOne|safe}} |
{{FourTwo|safe}} |
{{FourThree|safe}} |
{{FourFour|safe}} |
{{FourFive|safe}} |
{{FourSix|safe}} |
{{FiveOne|safe}} |
{{FiveTwo|safe}} |
{{FiveThree|safe}} |
{{FiveFour|safe}} |
{{FiveFive|safe}} |
{{FiveSix|safe}} |
{{SixOne|safe}} |
{{SixTwo|safe}} |
{{SixThree|safe}} |
{{SixFour|safe}} |
{{SixFive|safe}} |
{{SixSix|safe}} |
|


Have any Questions?
Mail Us Now
Repair Services
PC Repair
Laptop Repair
Home
About Us
Services
PC/MAC SERVICES
LAPTOP/MACBOOK SERVICES
Repairs
PC/MAC REPAIRS
LAPTOP/MACBOOK REPAIRS
Gallery
Contact Us
501-941-1352
COMING SOON


About Me
Hello and welcome to my About Me page. My name is Tristin and I'm 33 years old. I currently live in Redmond, WA working as a software integration engineer for a company which develops a real-time SaaS environment to manage automated dispensing solutions. I've attended the Art Institute of Seattle and have worked as a freelance graphic designer for many years.
I joined the US Navy right out of high school in 2005. I spent 10 years in as a submariner on the USS Ohio. Aboard, I was a Systems Administrator working on the multiple computer networks. With the Navy, I moved around from all over the East Coast to here in Washington. While on deployment, I've visited Guam, Australia, Japan, South Korea, the Philippines, and Singapore. I really enjoyed my time enlisted and I'm grateful for the opportunities it's given me.
Originally from Southern California, I've now lived in Washington since '07. It's quite a different atmosphere, but I love it up here. California will always hold a place in my heart, but Washington is now home. I just recently moved to Redmond where I'm able to bike to work every day.
Growing up I was always an animal fan. I've had hampsters, dogs, cats, and even horses. The last few years I lived in California, my family owned a small ranch that raised Peruvian Pasos. Currently, I have a 5 year old rescue cat name My Kitty Love. While weary of new people, she's a huge snuggler once she get's to know you. She's never far when I'm at the computer coding.
While I have quite a large extended family all over the US, I'm an only child. I'm thankful for the time my dad was able to spend with me growing up and the plentiful amount of friends I had, as I never had an issues not having any brothers and sisters.
I am currently engaged to my girlfriend of 6 years Anna. She's absolutely wonderful and I'm ecstatic to have her with me in life. She is my main motivation in life and she supports me through all of my projects and goals. I'm excited to complete the Code Fellows Javascript courses to move into the next chapter of my life. I'm hoping to transition into a front-end developer role where I can build great looking, functional web apps.
Favorite Movies
- The Thing (1982)
- Back to the Future
- Star Wars (OT)
- The Lord of the Rings
- Princess Mononoke
- Resevior Dogs
- Akira
- Saving Private Ryan
- Hackers
- Starship Troopers
Education and Work Experience
- VendNovation - Application Interface Engineer
- The Home Depot - Assistant Store Manager
- US Navy - ITS1(SS) Networked Systens Manager
- The Art Institute of Seattle - BFA in Graphic Design
- Network+ - Security+ - A+ - CCNA


We provide these floating point performance numbers as a guide to users to indicate the type of floating point rates they should expect while using PETSc. We have done our best to provide fair and accurate values but do not guarantee any of the numbers presented here.
See the "Profiling" chapter of the PETSc users manual for instructions on techniques to obtain accurate performance numbers with PETSc
Single Processor Performance
In many PDE application codes one most solve systems of linear equations
arising from the descretization of multicomponent PDEs, the sparse matrices computed
naturally have a block structure.
PETSc has special sparse matrix storage formats and routines to take advantage of that block structure to deliver much higher (two or three times as high) floating point computation rates. Below we give the floating point rates for the matrix-vector product for a 1503 by 1503 sparse matrix with a block size of three arising from a simple oil reservoir simulation.
The next table depicts performance for the entire linear solve using GMRES(30) and ILU(0) preconditioning.
These tests were run using the code src/sles/examples/tutorials/ex10.c with the options
mpiexec -n 1 ex10 -f0 arco1 -f1 arco1 -pc_type ilu -ksp_gmres_unmodifiedgramschmidt -optionsleft -mat_baij -matload_block_size 3 -log_view
Parallel Performance for Euler Solver
Scalability for Laplacian
A typical "model" problem people work with in numerical analysis for PDEs is the
Laplacian. Discretization of the Laplacian in two dimensions with finite differences
is typically done using the "five point" stencil. This results in a very sparse
(at most five nonzeros per row), ill-conditioned matrix.
Because the matrix is so sparse and has no block structure it is difficult to get very good sequential or parallel floating point performance, especially for small problems. Here we demonstrate scalability of the parallel PETSc matrix vector product for the five point stencil on two grids. These were run on three machines: an IBM SP2 with the Power2Super chip and two memory cards at ANL, the Cray T3E at NERSC and the Origin2000 at NCSA.
Since PETSc is intended for much more general problems then the Laplacian we don't consider the Laplacian to be a particularlly important benchmark; we include it due to interest from the community.
Notes: The problem here is simply to small to parallelize on a distributed memory computer.


In fact, their near-final version of a tiny notebook with a breakaway tablet screen absolutely kills anything Apple could possibly announce later this month. It’s not even close.
Paul Thurrott on an upcoming computer from Lenovo.
The not-even-a-product-yet that no one knows anything about from Apple doesn’t even come close to beating a not-yet-annonced, not-yet-final Lenovo tablet Paul Thurrott spent an hour and a half with yesterday.
Incredible. Via Daring Fireball


---
layout: member-page
title: Tomas San Miguel
class_of: 2019
bio: "I'm a programmer who has been designing and making games since I was little. It's pretty much the best feeling in the world to create a project that has a positive impact on somebody else's life. Plus, making games is basically the most fun thing to be doing. Joining GCS was one of the best decisions I ever made!
I was the president of GCS from Fall of 2016 until the Fall or 2018. The GCS game I'm most proud of is definitely Knight Night which was a hit on the Arcade Cabinet. I think my biggest accomplishment as President was modernizing the club by updating the bylaws and how we actually create teams.
I'm currently poised to take a full-time job at Amazon but I aim to move into the game industry when the time is right. I had the opportunity to work at Vicarious Visions in the Summer of 2018 and it was certainly the best work experience I have ever had.
I think absolutely anyone can (and should!) try their hand at making games. GCS is a pretty awesome place to give that a go!"
last_updated: November 15, 2020
# Optional
website: "https://tomassanmiguel.github.io/aboutme/"
previous_positions: {
2018: President,
2017: President,
2016: Director of Development
}
profile_pic: TomasSanMiguel.jpg
---


NIKE FREE TR FIT The Free TR Fit is designed with a lower environmental impact using environmentally preferred rubber, water-based cementing and recycled polyester. That means every step in the multi-directional flex groove outsole replicates the foot's natural movement and helps women get more out of their workout without leaving a huge environmental footprint. Everyone's a winner.


| Week XX YYYY |
A week number for a calendar week starting with a Monday. Use a leading 0 for the first 9 weeks. This is defined in ISO 8601. |
Week 01 2016 |
Update |
| Jan YYYY |
Month of January |
Jan 2016 |
Update |
| Feb YYYY |
Month of February |
Feb 2016 |
Update |
| Mar YYYY |
Month of March |
Mar 2016 |
Update |
| Apr YYYY |
Month of April |
Apr 2016 |
Update |
| May YYYY |
Month of May |
May 2016 |
Update |
| Jun YYYY |
Month of June |
Jun 2016 |
Update |
| Jul YYYY |
Month of July |
Jul 2016 |
Update |
| Aug YYYY |
Month of August |
Aug 2016 |
Update |
| Sep YYYY |
Month of September |
Sep 2016 |
Update |
| Oct YYYY |
Month of October |
Oct 2016 |
Update |
| Nov YYYY |
Month of November |
Nov 2016 |
Update |
| Dec YYYY |
Month of December |
Dec 2016 |
Update |
| Qtr 1 YYYY |
Financial quarter 1 - April to June YYYY |
Qtr 1 2016 |
Update |
| Qtr 2 YYYY |
Financial quarter 2 - July to September YYYY |
Qtr 2 2016 |
Update |
| Qtr 3 YYYY |
Financial quarter 3 - October to December YYYY |
Qtr 3 2016 |
Update |
| Qtr 4 YYYY |
Financial quarter 4 - January to March YYYY |
Qtr 4 2016 |
Update |
| YYYY |
A calendar year - as defined in ISO 8601 |
2016 |
Update |
| YYYY/YY |
The financial year - 1 April to 31 March. You can also use the format YY/YY. |
2016/17 or 16/17 |
Update |
| Water year YYYY |
The hydrological water year - 1 October to 30 September |
Water year 2016 |
Update |


Before Change
residual_dim = layer_in_channels[-residual]
self.projections.append(Linear(residual_dim, out_channels)
if residual_dim != out_channels else None)
if kernel_size % 2 == 1:
padding = kernel_size // 2
else:
padding = 0
self.convolutions.append(
ConvTBC(in_channels, out_channels * 2, kernel_size,
dropout=dropout, padding=padding)
)
After Change
Args:
dictionary (~fairseq.data.Dictionary): encoding dictionary
embed_dim (int, optional): embedding dimension
embed_dict (str, optional): filename from which to load pre-trained
embeddings
max_positions (int, optional): maximum supported input sequence length
convolutions (list, optional): the convolutional layer structure. Each
list item `i` corresponds to convolutional layer `i`. Layers are
given as ``(out_channels, kernel_width, [residual])``. Residual
connections are added between layers when ``residual=1`` (which is
the default behavior).
dropout (float, optional): dropout to be applied before each conv layer
def __init__(
self, dictionary, embed_dim=512, embed_dict=None, max_positions=1024,
convolutions=((512, 3),) * 20, dropout=0.1,
):
super().__init__(dictionary)


Another elephant found dead in Sabah, says Wildlife Dept
LAHAD DATU, Dec 9 — Another elephant was found dead in Sabah today.
Lahad Datu Wildlife Department officer Sylvester Saimin said the carcass was found in Bakapit near here at 6.30am by a plantation worker.
“We have gone to the scene and investigations are underway. We will give further information once the post-mortem is released,” he said.
Several elephants have been found dead in Kalabakan, Sungai Kinabatangan, Beluran over the past four months. — Bernama


| Package | Description |
|---|---|
| golad.bot |
This package provides bot related classes and interfaces.
|
| golad.lib |
This package provides classes and interfaces for observation and manipulation of GOLAD boards.
|
| golad.lib.impl |
This package provides abstract and concrete implementations of the concepts defined in
golad.lib |
| Modifier and Type | Method and Description |
|---|---|
E |
BotFactory.createBot(String opponentName,
String opponentVersion,
String opponentAuthor,
int boardWidth,
int boardHeight,
int initialCellCount,
CellState ownColor)
Returns a Bot ready to participate in the described GOLAD game.
|
| Modifier and Type | Field and Description |
|---|---|
static Set<CellState> |
CellState.ALIVE_STATES
The set of all CellStates which are
alive . |
static Set<CellState> |
CellState.BLUE_STATES
Convenience set that only contains
BLUE . |
static Set<CellState> |
CellState.DEAD_STATES
Convenience set that only contains
DEAD . |
static Set<CellState> |
CellState.RED_STATES
Convenience set that only contains
RED . |
| Modifier and Type | Method and Description |
|---|---|
CellState |
Board.getCellStateAt(int x,
int y)
Returns the current state of the cell at the specified coordinates.
|
CellState |
MoveFactory.getPlayerColor()
Returns the CellState representing an alive cell owned by the player that is given this MoveFactory.
|
CellState |
MutableBoard.setCellStateAt(int x,
int y,
CellState newState)
Changes the state of a cell.
|
static CellState |
CellState.valueOf(String name)
Returns the enum constant of this type with the specified name.
|
static CellState[] |
CellState.values()
Returns an array containing the constants of this enum type, in
the order they are declared.
|
| Modifier and Type | Method and Description |
|---|---|
Move |
MoveFactory.createTestMove(Board board,
CellState player,
Move.Type type,
int x,
int y,
int[] sx,
int[] sy)
Creates a Move validated against the provided Board for the provided player.
|
CellState |
MutableBoard.setCellStateAt(int x,
int y,
CellState newState)
Changes the state of a cell.
|
| Modifier and Type | Method and Description |
|---|---|
int |
Board.getNeighborCellCount(int x,
int y,
Set<CellState> states)
Returns the current number of neighbors of a specified cell, that are in any of the specified
CellState s. |
int |
Board.getTotalCellCount(Set<CellState> states)
Returns the current number of cells in any of the specified
CellState s. |
| Modifier and Type | Method and Description |
|---|---|
CellState |
DefaultBoard.getCellStateAt(int x,
int y) |
CellState |
DelegateBoard.getCellStateAt(int x,
int y) |
CellState |
DefaultAbstractMoveFactory.getPlayerColor() |
CellState |
DefaultBoard.setCellStateAt(int x,
int y,
CellState newState) |
| Modifier and Type | Method and Description |
|---|---|
CellState |
DefaultBoard.setCellStateAt(int x,
int y,
CellState newState) |
| Modifier and Type | Method and Description |
|---|---|
int |
AbstractBoard.getNeighborCellCount(int x,
int y,
Set<CellState> states) |
int |
DelegateBoard.getNeighborCellCount(int x,
int y,
Set<CellState> states) |
int |
AbstractBoard.getTotalCellCount(Set<CellState> states) |
int |
DelegateBoard.getTotalCellCount(Set<CellState> states) |
| Constructor and Description |
|---|
DefaultAbstractMoveFactory(Board board,
CellState player)
Creates a new DefaultAbstractMoveFactory.
|
DefaultBoard(int w,
int h,
CellState init)
Creates a new board with the specified width and height, initializing each cell with the provided
CellState . |


Why Are You Wearing That
Parachute?
By Robin McCulloch
I remember the gesture very clearly. It was done with a care
for detail that informed all the work we did as improvisational
performers. It was like seeing one of those international
symbols inside the red circle, “no smoking,” “no
left turn” or “no dogs allowed.” I would
be on stage in front of a couple of hundred people, improvising
a scene I had pitched to one of my improv collaborators. Suddenly
you see the fear in their eyes; the hand would go to the chest
as if clasping something and then the distinct pull away from
the chest followed by the smile, half mocking, half seeking
forgiveness. Your improv partner had “hit the chutes”.
The gesture was that of pulling the ripcord on a parachute
and meant that they were bailing out. They sensed the scene
was going down in flames and as it hadn’t been there
idea in the first place, why stick around for the crash.
Does this have a familiar ring? Have you felt the clarion
call of the washroom sirens just as the meeting took a turn
for the worse? Or watched a colleague bail out on you when
things started to get tough?
And we had no real excuse. We were supposed to be, arguably,
some of the best professional improvisers in the world. We
were on stage at the Toronto wing of The Second City, the
Mecca of improvisational comedy. A stage that had been, or
would be, graced by John Candy, Catherine O’Hara, and
the rest of their SCTV comrades, Mike Myers, Gilda Radner
and Dan Aykroyd…a very long list of accomplished improvisers
and actors. Also, the concept of “hitting the chutes”,
as we referred to it, was against the very principles of improvisation.
Support, agreement, acceptance and saying “yes”
to each new offer, these were the foundation of good improvisation.
So why would such accomplished improvisational performers
abandon each other to certain theatrical death? Maybe to understand
the fear you need to be aware of exactly what was being attempted
in the first place. There is a cyclical nature to the creative
process that exists at The Second City so it’s always
hard to know where to break into that cycle to start the explanation.
But let’s assume that a show has already been created
by you and your fellow cast members. Each night you would
do that set show, two acts, ninety minutes total, on average,
of memorized material. Then after taking a curtain call you
would get suggestions from the audience in various categories:
current events, occupations, pet peeves, etc. You would take
the suggestions back stage while the audience, you hoped,
would seek out that perfect mix of alcohol intoxication that
makes the jokes seem funnier but doesn’t make the audience
think they’re funnier than the people on stage.
The Pitch
Once you have the suggestions backstage, posted on the bulletin
board, you would immediately start pitching ideas to each
other based on a combination of suggestions or a single suggestion
or, to be honest, on something you had thought of that afternoon
while gazing at a waitress in a bar. You would have fifteen
minutes to pitch a couple of ideas, get someone to buy into
one or more of them, rope someone into the thankless roll
doing the grunt work to introduce your brilliant concept,
exchange some quick ideas about characters, grab a drink and
smoke before the lights start coming back up for the post-show
improv set.
Sound like some work meetings you’ve been in lately?
No time to solve too many problems while the folks that pay
your salary wait to see what kind of brilliant concepts you
discover.
While some of the other performers are out on stage taking
their chances you’re backstage, going over, in your
head, how you imagine the scene playing out. Then your turn
arrives. The lights come up to find you on stage and immediately
things start to change from the course you had imagined. The
performer you had enlisted to do the compulsory role of the
hotel Doorman has decided that the scene really revolves around
him. It is no longer a scene about two lovers sneaking into
a hotel for an afternoon tryst, but one about a Doorman who
secretly suffers from leprosy. Some initial shtick about a
one-handed Doorman suddenly makes your original partner decide
that the scene is no longer what they had agreed to and they
are refusing to enter. It doesn’t take long for the
Doorman to realize the leprosy joke is just that, a joke,
and will not carry a scene very far. He uses his good hand
to clasp the imaginary ripcord on his chest, hits the chute
and exits, leaving you alone, looking at your watch as the
lights fade to a smattering of confused applause.
 Suddenly he has a second
possibility that he has “just thought of” and
the other members of the team have come down with laryngitis.
The Post Mortem
What went wrong is that a group of highly competitive individuals
were attempting create something new in front of two hundred
people who had just seen ninety minutes of one laugh after
another. The audience didn’t know that the set show
they had just laughed through had started out as first time
improvisations in an improv set like the one they were now
watching. That it had been worked, re-worked, re-written and
rehearsed for months. No one told the audience that the performers
were abandoning the principles that made them successful.
How could they know that the very laughs that the performer
got as they backed off stage, at the expense of the scene
and fellow performers, were dooming the scene to failure?
I am sure you have all witnessed a fellow colleague getting
some laughs as they threw someone to the wolves to save their
own hide. You watch all that work go down the drain because
someone started feel the pressure and decided to hit the chute.
So what is the difference, then, between success and failure
in improvisation? Pretty much the same as it is in other aspects
of work and life. You can usually trace it back to commitment.
How much do you buy-in to the concept in the first place?
How committed are you to the team? If saying “yes”
is really just a subtly disguised “no” in the
form of “okay I’ll go out there with you but I
don’t think this is going to work”, then you can
almost hear the ripcord being pulled as the lights come up.
That gentle fluttering you hear is the room emptying even
though the bodies may still be there.
The Solution
To improvise well, you commit yourself on two levels, first,
to the principles of improvisation, acceptance, support, justification,
saying “yes”, and second, to the specifics of
the scene you are improvising. And your commitment can’t
be dependent on things staying the same because change is
inevitable.
The audiences at The Second City are usually very forgiving
because they understand that making it up on the spot is difficult
but is also rewarding when it all comes together in a magical
experience that seems too good to believe. But it is one thing
to be in the audience when it doesn’t come together
and quite another to be one of those poor souls on stage,
descending into comedy hell. Nothing quite focuses the survival
instincts like that first smell of failure; the first realization
that, Martian surgeons discovering why we have an appendix,
may only be funny to you. And once the not-funny veil starts
to descend over a scene most uncommitted improvisers start
to hear their mothers calling them home for dinner or if not
for dinner at the very least, OFF STAGE!
But when you see improvisation that is committed from the
start, ideas that seemed doomed at birth suddenly take the
most unexpected turns and become these amazing products of
positive cooperation. The desperate search for the “Big
Idea” seems unnecessary. “Big Ideas” go
nowhere without support and commitment. “Bad ideas”
can develop into great concepts with a supportive, committed
process.
The Second City was my office. Improvisation was the work
I did there. And the one thing above all others that made
the difference between failure and success was the level of
commitment.
Understanding the value of real commitment, to the team
and to the concept, can improve a team’s success rate
and innovative potential dramatically.
Think about this the next time you join a new project or
things seem to be going off the tracks or you realize your
Doorman only has one hand. When you feel yourself reaching
for that imaginary ripcord, ask yourself if you’re really
committed or you’re just “hitting the chute”?
Throw your parachute in the garbage because nothing is more
exciting or rewarding than using your support and imagination
to turn defeat into victory. And improvisation embodies
the principles that allow you to create solutions in a parachute
free workplace.
|


$$\lim_{x\to{c}}f(x) = L$$
In words:
The limit of the function $f(x)$ as $x$ approaches $c$ is the value of the function $L$ at that point
Or from Wikipedia:
$f(x)$ can be made to be as close to $L$ as desired by making $x$ sufficiently close to $c$. In that case, the above equation can be read as "the limit of $f$ of $x$, as $x$ approaches $c$, is $L$
Or mathematically:
Let $\delta$ and $\epsilon$ be two positive numbers:
$$ \begin{aligned} \delta &\in \mathbb{R}_{>0}\\ \epsilon &\in \mathbb{R}_{>0} \end{aligned} $$
Then we can write:
$$\lim_{x\to{c}}f(x) = L$$
Means that for all $x \ne c$
$$\lvert x−c \lvert < \delta \implies \lvert f(x)−L\lvert < \epsilon$$
So for every $\epsilon$ there is a $\delta$ such that the above formula holds.
Let us define following piecewise function
$$f(x) = \begin{cases} \frac{x^2}{100}+10 & \text{if } x < 0\\ 20 & \text{if } x = 0\\ \frac{x^2}{100}+10 & \text{if } x > 0\\ \end{cases} $$
The limit $L$ of the piecewise function for $x\to{0}$ is $10$
You can use the following slider to regulate $\epsilon$
You can use the following slider to regulate $\delta$
Watch how no matter how small you make $\epsilon$, you can always find a $\delta$ such that the $\epsilon$-$\delta$ definition still holds. If the definiton does not hold, the vectors representing $\delta$ willbe coloured red
Let us define following piecewise function
$$f(x) = \begin{cases} \frac{x^2}{100}+5 & \text{if } x < 0\\ 10 & \text{if } x = 0\\ \frac{x^2}{100}+15 & \text{if } x > 0\\ \end{cases} $$
The limit $L$ of the piecewise function for $x\to{0}$ comming from the left is $5$. However, the right-sided limit is 15. Which means the above delta-epsilon definition of limit does not hold!
Let us see what we get when we suppose the limit is 5:
You can use the following slider to regulate $\epsilon$
You can use the following slider to regulate $\delta$
Everything from the above still holds, until we let $\epsilon$ get smaller then 10. From that moment there is no delta for the right side of the piecewise fucntion as there is no value defined for $x$ which result in the desired value of $y=f(x)$


Arun Venkatraman
PhD Robotics, Engineer at Aurora Innnovation working on
self-driving vehicles.
I was a PhD student at the Robotics Institute, Carnegie Mellon University working with Dr. J. Andrew (Drew) Bagnell and Dr. Martial Hebert, focusing on
the intersection of machine learning and robotics. I have also often collaborated with Dr. Byron Boots from the Georgia Institute of Technology.
See my Google Scholar or CMU Robotics
Institute page for a more complete publication list.
Thesis
- Training Strategies for Time Series: Learning for Prediction, Filtering, and Reinforcement Learning
Arun Venkatraman
Comittee: Drew Bagnell, Martial Hebert, Jeff Schneider, Byron Boots.
[pdf] [video]
Selected Refereed Publications List.
- Improved Learning of Dynamics for Control
Arun Venkatraman, Roberto Capobianco, Lerrel Pinto, Martial Hebert, Daniele Nardi, and J. Andrew Bagnell
International Symposium on Experimental Robotics (ISER) 2016
[paper]
[code]
- Inference Machines for Nonparametric Filter Learning.
Arun Venkatraman, Wen Sun, Martial Hebert, Byron Boots. J. Andrew Bagnell.
International Joint Conference on Artificial Intelligence (IJCAI) 2016
[paper]
- Learning to Filter with Predictive State Inference Machines
Wen Sun, Arun Venkatraman, Byron Boots. J. Andrew Bagnell.
International Conference on Machine Learing (ICML) 2016
[paper]
- Online Instrumental Variable Regression with Applications to Online Linear System
Identification.
Arun Venkatraman, Wen Sun, Martial Hebert, J. Andrew Bagnell, Byron Boots.
AAAI 2016.
[paper w/ appendix]
- Autonomy Infused Teleoperation with Application to BCI Manipulation.
Katharina Mulling, Arun Venkatraman, Jean-Sebastien Valois, John Downey, Jeffrey Weiss, Shervin Javdani,
Martial Hebert, Andrew Schwartz, Jennifer Collinger, J. Andrew Bagnell.
RSS 2015.
[Best Systems Paper at RSS 2015]
[paper] [citation]
[video]
- Improving multi-step prediction of learned time series models.
Arun Venkatraman, Martial Hebert, J. Andrew Bagnell.
AAAI 2015.
[paper]
[code]
Contact information:
Arun Venkatraman
arunvenk [at symbol] cs [dot] cmu [another dot] edu
Updated 01/07/2018. © Arun Venkatraman


Gateway
BOT
30-Aug-18 03:48 PM
[dscrdeql] <CowboyCrypto- Founder> they cant have much left honestly.
[dscrdeql] <CowboyCrypto- Founder> I've bought close to 6 million coins from them
[dscrdeql] <SwimedDragon>
[dscrdeql] <SwimedDragon>
[dscrdeql] <SwimedDragon> Very nice at these prices!
[dscrdeql] <CowboyCrypto- Founder> and I dont have a coin on the exchange for under 1000 sats
[dscrdeql] <SwimedDragon> under 1000 sats or under the 9 digits 1000 sats?
[dscrdeql] <CowboyCrypto- Founder> under 1000 sats.
[dscrdeql] <CowboyCrypto- Founder> lol I know better than to play into that game.
[dscrdeql] <SwimedDragon> I think most of us bought everything at least below 20 sats since it was sitting there for a long time
[dscrdeql] <CowboyCrypto- Founder> super cheap considering the ico price was like 30 cents usd
[dscrdeql] <SwimedDragon> Yeah, I think we're very lucky with that. I do feel bad for people that paid 30 cents per EQLI for it
[dscrdeql] <SwimedDragon> I mean, it's an incredible loss if you look at today's price. Offcourse I hope most of them are smart enough to hold
[dscrdeql] <Llama-Admin> that'd be a super long hold
[dscrdeql] <SwimedDragon> Lol, how much is current price in cents?
[dscrdeql] <Llama-Admin> they should just buy more to make up for it
[dscrdeql] <SwimedDragon> Like 0.01 or less.
[dscrdeql] <SwimedDragon> Yeah true
[dscrdeql] <SwimedDragon> But still, if you paid a few hundred or even a thousand, I can imagine it must suck to see the price down at this
[dscrdeql] <CowboyCrypto- Founder> our early investors are ok with where we are at right now because they know what is coming.
[dscrdeql] <Llama-Admin> Am I considered an early investor?
[dscrdeql] <CowboyCrypto- Founder> this current situation is easilly turned. one person walking in and market buying 1 btc worth sends this project into orbit.
[dscrdeql] <NWhiskeyTango> I bought an ish ton 0.00000009 BTC so i think i'm good still, haven't check prices lately
[dscrdeql] <NWhiskeyTango> 7 zeroes ^ lol
[dscrdeql] <CowboyCrypto- Founder> I guess you were an early one llama... but I was referring to the ones who bought in before we ever announced anything
[dscrdeql] <SwimedDragon> The supply that isn't sold at Ico, is there already some news on what's going to happen with that?
[dscrdeql] <CowboyCrypto- Founder> I cant say anything on that one yet
[dscrdeql] <CowboyCrypto- Founder> it will all come out soon.
[dscrdeql] <c2k> between cowboy founder and the rest of us i would think we bot at least 10mm
[dscrdeql] <CowboyCrypto- Founder> you can see part of the allocation on our site, its the team allocation, advisor allocation, etc etc. but the remaining unsold coins will be put to good use
[dscrdeql] <CowboyCrypto- Founder> I think you all will be happy with what we have planned
[dscrdeql] <SwimedDragon> I'm too curious now haha
[dscrdeql] <NWhiskeyTango> I looks low still just checked, wish i had some more BTC to play with :/
[dscrdeql] <c2k> maybe the unsold supply gets burned :tipsy:
[dscrdeql] <KQweci-Mod> I'm loser I guess
[dscrdeql] <CowboyCrypto- Founder> why you say that?
[dscrdeql] <SwimedDragon> Hopefully a part of it can be hold for exchange payments in the future


Jefferson County Public Schools
School and Community Nutrition Services
Food Portfolio
Code Louisville Portfolio
Fun and Games
About
Contact
Nutrition Initiatives Request Form
Name
Gallery will go here


Age: 44
Leonardo Wilhelm DiCaprio; born November 11, 1974 is an American actor and film producer. He has been nominated for six Academy Awards, four British Academy Film Awards and nine Screen Actors Guild Awards, winning one of each award from them and three Golden Globe Awards from eleven nominations.


Set a PIN #
This PIN # will used to open the wallet. Don't forget it; if you do, you may lose access to your mobile wallet.
Confirm PIN #
Enter your pin once more to continue.
We could not instantiate our secure storage service on your device. This means you cannot set a pincode and/or save your wallet seeds on your device. Whenever you want to transfer funds out of your wallet, you will be requested to enter your wallet seed again. Without your seed your funds will most likely be irretrievably lost.
This PIN # will used to open the wallet. Don't forget it; if you do, you may lose access to your mobile wallet.
Enter your pin once more to continue.


Example 3: Tabpanel Accessibility Plugin
Modified version of PayPal Accessibility Plugin for Carousel
Accessibility Features
Keyboard Support
- Tabs
- First interactive content of the carousel
- A "Tab" is one of the dots indicating the number slides (e.g. tabpanels) in the carousel.
- Tab key moves keyboard focus into and out of the list of tabs.
- Left and up arrow expose the previous slide.
- Right and down arrow expose the next slide.
- Tabpanels
- Second section of the carousel for possible interactive content
- Tab key moves keyboard focus to any interactive content in a panel (i.e.. typically links and form controls).
- Only interactive elements on the visible slide can get focus.
- Some carousels may not include links, form controls or other interactive content.
- Previous and Next Buttons Buttons
- Tab key moves keyboard focus into and out of the button elements.
- Enter or space can be used to activate the button.
- Since
bootstrap.js
uses a
elements to define previous and next slide buttons, keyboard events need to be added to support the space key to support the default way to activate a "button", since a
elements only respond to the enter key
- "Pause/Play Carousel" Button (at beginning of page)
- Uses
button
element keyboard support to toggle the carousel on and off.
- Button is inside a
aside
element (e.g. defines a complementary landmark) with aria-label="Carousel Pause/Play Button"
attribute.
Keyboard Focus Styling
- Tabs
- When a "Tab" receives focus a box appears around the list of tabs.
- The tabs styling changes to include a partially transparent background image.
- The currently selected tab is solid white
- Tabpanels
- Styling of interactive content is controlled by the authors style sheets
- Previous and Next Buttons Buttons
- When a button receives focus a border becomes visible and a background gradient similar to the hover styling appears.
- "Pause/Play Carousel" Button (at beginning of page)
- The
button
is positioned off screen using CSS absolute positioning when it does not have keyboard focus.
- The
button
is positioned in the upper left corner of the screen when it receives keyboard focus and becomes visible.
Low Vision Support
- "tabs" for indicating number of slides and selected slide
- Increased size of round tabs for controlling which slide is displayed and indicating the total number of slides in the carousel.
- Increased contrast of round tabs and highlighting of selected tab.
- Color contrast of text in slide caption
- Mouse hover adds a background image to slide caption area to improve color contrast.
- Keyboard focus on controls and links within the carousel will also add the background image.
Use of ARIA Roles
complementary
Landmark Role
- The
complementary
landmark role is used to identify all the content and interactive controls
associated with the carousel widget.
- The landmark provides a means to navigate to and identify the carousel features.
tablist
and tab
Roles
- Are defined for the dots used to indicate the number of slides and which slide is selected.
tabpanel
Role
- Are defined for the slide content.
button
Role
- The
button
roles is used to override semantics of the a
element
used to define the previous and next slide buttons.
- Links typically take you to a new web page or a section of a web page, while buttons change
the state of a web page, in this case which slide is visible.
Screen Reader Specific Features
- Carousel Pause/Play Button
- Added as first item on the page using scripting.
- In virtual mode (e.g. windows screen reader) a screen reader user can identify that
there is a carousel and stop the rotation
- When the virtual cursor is on content within a slide and the slide changes the virtual cursor
moves the virtual cursor back to the top of the page. Kind of like ground hog day for a screen
reader user.
- Carousel Description
- At the beginning of the carousel, off screen content is used to identify and describe the carousel.
bootstrap.js
uses a
elements to define previous and next slide buttons, keyboard events need to be added to support the space key to support the default way to activate a "button", since a
elements only respond to the enter keybutton
element keyboard support to toggle the carousel on and off.aside
element (e.g. defines a complementary landmark) with aria-label="Carousel Pause/Play Button"
attribute.- Tabs
- When a "Tab" receives focus a box appears around the list of tabs.
- The tabs styling changes to include a partially transparent background image.
- The currently selected tab is solid white
- Tabpanels
- Styling of interactive content is controlled by the authors style sheets
- Previous and Next Buttons Buttons
- When a button receives focus a border becomes visible and a background gradient similar to the hover styling appears.
- "Pause/Play Carousel" Button (at beginning of page)
- The
button
is positioned off screen using CSS absolute positioning when it does not have keyboard focus. - The
button
is positioned in the upper left corner of the screen when it receives keyboard focus and becomes visible. - "tabs" for indicating number of slides and selected slide
- Increased size of round tabs for controlling which slide is displayed and indicating the total number of slides in the carousel.
- Increased contrast of round tabs and highlighting of selected tab.
- Color contrast of text in slide caption
- Mouse hover adds a background image to slide caption area to improve color contrast.
- Keyboard focus on controls and links within the carousel will also add the background image.
complementary
Landmark Role- The
complementary
landmark role is used to identify all the content and interactive controls associated with the carousel widget. - The landmark provides a means to navigate to and identify the carousel features.
tablist
andtab
Roles- Are defined for the dots used to indicate the number of slides and which slide is selected.
tabpanel
Role- Are defined for the slide content.
button
Role- The
button
roles is used to override semantics of thea
element used to define the previous and next slide buttons. - Links typically take you to a new web page or a section of a web page, while buttons change the state of a web page, in this case which slide is visible.
- Carousel Pause/Play Button
- Added as first item on the page using scripting.
- In virtual mode (e.g. windows screen reader) a screen reader user can identify that there is a carousel and stop the rotation
- When the virtual cursor is on content within a slide and the slide changes the virtual cursor moves the virtual cursor back to the top of the page. Kind of like ground hog day for a screen reader user.
- Carousel Description
- At the beginning of the carousel, off screen content is used to identify and describe the carousel.


Enhance your website with tabbed content easily.
Very simple and intuitive usage with seamless integration with Odoo website editor. Create or remove new tabs just by clicking option buttons.
Each tabs accept any snippet the website normally accepts, just select the tab and drag & drop it inside.
Seamless integration with all major Odoo themes and custom themes based on bootstrap.


I would feel relaxed talking with a digital copy of a person.
Strongly Disagree
Moderately Disagree
Slightly Disagree
Neutral
Slightly Agree
Moderately Agree
Strongly Agree


Combo completo por tan solo $10.000 incluye agrandadas papas, gaseosa, helado y mas cosas
Obten tu CUPÓN¡Some quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereDescuento en un pc mac super poderoso y con todos los juegues muchas caracteristicas y etc.
Obten tu CUPÓN¡Some quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhereSome quick example text to build on the card title and make up the bulk of the card's content.
Go somewhere